# Pfizer Q3 Revenue Boosts 2026 Guidance

> Pfizer's $16.6B Q3 revenue and 32% growth in newer medicines lift 2026 financial outlook.
- Title: Pfizer Q3 Revenue Boosts 2026 Guidance · Pulse 2.0 | Shortify
- Summary: Pfizer's $16.6B Q3 revenue and 32% growth in newer medicines lift 2026 financial outlook.
- Keywords: pfizer, q3 revenue, 2026 guidance, newer medicines, operational revenue growth, commercial performance, obesity program, oncology treatments, vaccines, financial guidance, Pulse 2.0
- Source: Pulse 2.0 — https://pulse2.com/pfizer-16-6-billion-q3-revenue-supports-higher-2026-guidance-as-newer-medicines-grow-32
- Author: Amit Chowdhry
- Published: 2026-11-06T13:55:13+00:00
- Read time: 1 min
- Topics: pfizer, q3 revenue, 2026 guidance, newer medicines, operational revenue growth, commercial performance, obesity program, oncology treatments, vaccines, financial guidance, startups, business
## Pfizer Q3 Revenue
Pfizer reported third-quarter 2026 revenue of $16.583 billion, slightly below prior-year revenue of $16.654 billion.
## Operational Revenue Growth
Excluding COVID-19 products, Pfizer's newer medicines delivered 7% operational revenue growth.
## Product Performance
Pfizer's launched and acquired products generated 32% operational revenue growth.
## Key Product Gains
Eliquis revenue increased $513 million (25%), Padcev grew $255 million (55%), and Vyndaqel rose $193 million (12%).
## Product Challenges
Paxlovid revenue dropped $771 million (63%) as Comirnaty sales fell $339 million (29%).
## Financial Guidance
Pfizer raised full-year 2026 revenue guidance to $62-64 billion from $60.5-62.5 billion.
## CEO Statement
Dr. Albert Bourla highlighted strong commercial momentum and pipeline progress for long-term shareholder value.

> Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value. Our obesity program continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline. With a robust slate of expected catalysts ahead, i believe we’re well positioned to deliver meaningful new medicines for patients and lasting value in the years ahead.
## Key takeaway

Pfizer raised full-year 2026 revenue guidance to $62-64 billion after strong Q3 performance with newer medicines growing 32% operationally.